CD276 and neuroblastoma: Aiming at controlling neurotoxicity of GD2-CAR-T cells, SynNotch gated CAR-T cells recognizing GD2 ganglioside as the gate and B7H3, i.e., CD276, as the target (Figure 4), were assayed against neuroblastoma in vitro and in xenograft mice demonstrating the specificity and efficacy of the therapy [128].